ABBV: AbbVie Inc. - Summary | Jitta

AbbVie Inc.

NYSE:ABBV

Price
$102.79
Loss Chance
42.8%
6.53JITTA SCORE
51.61%Under Jitta Line
Jitta Ranking
56 / 939
703 / 4,286
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (56)
Recent Business Performance (27)
Financial Strength (71)
Return to Shareholders (70)
Competitive Advantage (71)
Jitta Signs
Revenue and EarningConsistent Growth in the past 5 years
Operating MarginConsistent
Dividend PayoutIncreasing Every Year
Share RepurchaseEvery Year
CapExVery Low
Interest Coverage RatioVery Good
SG&A to SalesDecreasing Every Year
Recent Business PerformanceEarning decline 21.80% in the last quarter (yoy)
Key Stats
Jitta Score
Jitta Line
6.53
51.61%
1.44
157.40%
2.30
292.60%
Biotechnology
3.21
60.68%
7.12
56.18%
5.76
24.01%
COMPANY DESCRIPTION
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström’s macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson’s disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Frontier Medicines, Corp.; Jacobio Pharmaceuticals; I-Mab; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.